Advanced liver fibrosis and/or mild liver cirrhosis research hub

A Double-Blind Placebo-Controlled Randomised Phase 1b Study of the Pharmacokinetics of ALE.F02 in Patients with Advanced Liver Fibrosis and/or with Mild Cirrhosis

This study is testing a new medicine, ALE.F02, in adults with advanced liver scarring or early-stage liver disease. It aims to understand how the body uses the medicine, comparing it to a dummy treatment, to see if it could help. This is an early trial to check its effects and safety.